Semax: Structure and Receptor Studies
A review of Semax as an ACTH(4-10) analogue: its structure, the BDNF and melanocortin-receptor mechanisms reported in rodent models, and the gaps in the literature.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide analog of the ACTH(4-10) fragment, developed in Russia in the 1980s by Nikolai Myasoedov and colleagues at the Russian Academy of Sciences. Unlike intact ACTH, Semax lacks steroidogenic activity — it does not stimulate cortisol production — while retaining the receptor activity of the ACTH fragment that the rodent literature investigates. It holds a registration in Russia but no UK or EU marketing authorisation.
BDNF Upregulation: The Core Mechanism
The most consistently replicated finding in Semax research is its ability to upregulate brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB (tropomyosin receptor kinase B). BDNF is critical for neuronal survival, synaptic plasticity, long-term potentiation (LTP), and the support of cholinergic and dopaminergic neuron populations. In the hippocampus — a region central to declarative memory and particularly vulnerable to ischemic injury — Semax administration in rodents produces robust BDNF mRNA increases (2-5 fold over baseline) within 24 hours, persisting for up to 3 days after a single administration, according to the published rodent studies.
The mechanism involves Semax binding to melanocortin receptors (MC4R and MC5R are the primary candidates, though this remains incompletely characterized) and downstream activation of CREB (cAMP response element-binding protein), a transcription factor that drives BDNF gene expression. Separately, Semax modulates NGF (nerve growth factor) expression in cholinergic basal forebrain neurons, which the authors propose as a second pathway in the rodent models studied.
Neuroprotective Mechanisms in Ischemia
Much of the Semax literature uses rodent ischemia models. In middle cerebral artery occlusion (MCAO) rat studies, the authors report smaller infarct volumes in animals given Semax within 3 hours of ischemia onset than in controls. The mechanisms proposed in these studies are multi-factorial:
- Anti-excitotoxic: Semax reduces post-ischemic glutamate release and attenuates NMDA receptor hyperactivation, limiting calcium-mediated neuronal necrosis in the ischemic penumbra.
- Anti-inflammatory: Suppression of microglial activation and reduction of TNF-α, IL-1β, and IL-6 in the peri-infarct zone.
- Anti-apoptotic: Upregulation of Bcl-2 and downregulation of Bax and caspase-3 in threatened neurons.
- Pro-angiogenic: Enhanced VEGF expression and microvessel density in the peri-lesion area at 7–14 days post-ischemia in the rat models studied.
Semax degrades rapidly in aqueous solution (t½ ~15 minutes at 37°C due to aminopeptidase activity). Research solutions should be prepared fresh immediately before use, or stored as lyophilized aliquots and reconstituted just before the assay.